AcornMed Raises RMB 200 Million in Series B Financing Led by Yikai Venture Capital
AcornMed, a tumor precision medicine specialist based in Beijing, has reportedly raised RMB 200 million...
Biotech
Hengrui Pharmaceuticals Receives New Approval for Remimazolam Tosylate
China-based Jiangsu Hengrui Pharmaceuticals (SHA: 600276) has announced one new supplementary approval for its gamma-aminobutyric...
Jiangsu Vcare PharmaTech Raises RMB 200 Million in Series B Financing Round
China-based Jiangsu Vcare PharmaTech Co. Ltd has reportedly raised over RMB 200 million (USD 28.67...
Fosun Pharma’s Avatrombopag Receives NMPA Review for Chronic ITP Indication
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced that another...
Nanjing Pharmaceutical to Acquire Majority Stakes in Three Jiangsu Subsidiaries
China-based Shanghai-listed Nanjing Pharmaceutical Co., Ltd (SHA: 600713) is set to acquire a respective 55%,...
MSD and Kelun Biotech Ink Record-Breaking ADC Deal
Merck, Sharp & Dohme (MSD, NYSE: MRK) has set a new benchmark for the largest...
Waker Bioscience Raises Angel Funding for ISA Technology Upgrades
Waker Bioscience, an integration site analysis (ISA) specialist based in Shanghai, has reportedly raised “tens...
Ascletis Pharma Receives USPTO Notice for ASC10 Patent
China-based Ascletis Pharma Inc. (HKG: 1672) has announced receiving the Notice of Issuance from the...
PCAOB Report Signals Relief for US-Listed Chinese Biotechs
A report issued last week by the US Public Company Accounting Oversight Board (PCAOB) indicated...
GenFleet and Merck KGaA Partner on European Clinical Study for KRAS G12C Inhibitor
China-based GenFleet Therapeutics Inc. has announced a European multi-center clinical study and drug supply agreement...
Doer Bio and MSD Collaborate on Clinical Trial for Anti-Claudin18.2 Antibody DR30303
China-based Zhejiang Doer Biologics Co., Ltd has announced a clinical trial collaboration agreement with US...
Everest Medicines Achieves Preclinical Milestone for mRNA Rabies Vaccine
China-based Everest Medicines (HKG: 1952) has announced that the company has achieved the preclinical proof-of-concept...
Alternative Bio Completes $15M Seed Round to Advance Cancer Therapeutics
Singapore-based Alternative Bio Inc. has announced the completion of a seed financing round at USD...
JW Therapeutics Presents Carteyva Data at ASH Annual Meeting
China-based JW Therapeutics (HKG: 2126) presented the latest clinical data on Carteyva (relmacabtagene autoleucel injection)...
Sequanta Technologies and Iomics Bio Collaborate on Multi-Omics Research
Sequanta Technologies, a multi-omics research and clinical service provider based in Shanghai, and Iomics Biosciences...
Harbour BioMed’s Nona Biosciences Licenses Antibody Platform to Kelun-Biotech
Harbour BioMed (HKG: 2142), a biotech operating out of the Netherlands, the United States, and...
MaxHealth Biotechnology Completes Series B+ Financing Round
Chengdu-based vaccine developer MaxHealth Biotechnology LLC announced the completion of a Series B+ financing round...
Everlife Biomed Raises Pre-Series A+ Funding for Immune Exemption Platform
Beijing-based Everlife Biomed reportedly raised “tens of millions” of renminbi in a pre-Series A+ financing...
Akeso Biopharma Plans IPO on Shanghai’s STAR Market
China-based antibody developer Akeso Biopharma (HKG: 9926) announced that its board of directors has decided...